Healthcare >> CEO Interviews >> July 24, 2013

Interview with the President and CEO: Endologix, Inc. (ELGX)

John McDermott joined Endologix, Inc., in May 2008 as President and Chief Executive Officer. Mr. McDermott has over 20 years of executive management, sales, marketing and finance experience in the vascular device industry. From 2002 to 2007 he served as President of Bard Peripheral Vascular, a division of C.R. Bard, Inc. Mr. McDermott previously served as President of Global Sales for C.R. Bard, Inc.'s vascular surgery and endovascular businesses, with responsibilities for managing a worldwide direct sales force with more than 200 representatives. Prior to that, he served for four years as President of C.R. Bard, Inc.'s division IMPRA, Inc., where he was responsible for global operations, including sales, marketing, research and development, manufacturing and finance. From 1990 to 1996, Mr. McDermott served as Chief Financial Officer and later Vice President and Chief Operating Officer of IMPRA, Inc., prior to its acquisition by C.R. Bard, Inc. He is an active leader within the vascular community and is currently on the board of directors of the International Society of Endovascular Specialists.  Profile
TWST: Endologix is a developer and manufacturer of minimally invasive treatments for vascular diseases. Can you give us the overview of the company, including its history, products and